Business Wire

TII

8.3.2021 14:09:09 CET | Business Wire | Press release

Share
Abu Dhabi’s Technology Innovation Institute Appoints International Experts to Board of Advisors at Secure Systems Research Centre

Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the appointment of international experts in the field of systems security to the Board of Advisors of its Secure Systems Research Centre (SSRC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005482/en/

Secure Systems Research Centre is one of the initial seven dedicated centres at TII and is among the few global centres of its kind to bring together experts to conduct groundbreaking research in the field of secure systems. The distinguished new Board have combined expertise in security and resilience relating to autonomous computing and will guide the efforts of the Centre’s research team in developing end-to-end solutions to protect cyber-physical and autonomous systems.

The Board of Advisors comprises:

Prof. Ernesto Damiani, Professor, Department of Electrical Engineering and Computer Science, Senior Director, Artificial Intelligence & Intelligent Systems Institute, Director of the Center for Cyber Physical Systems (C2PS), Khalifa University in the UAE, whose research interests include secure service-oriented architectures, privacy-preserving big data analytics and cyber-physical systems security.

Dr Hoda Alkhzaimi, Research Assistant Professor at New York University Abu Dhabi (NYUAD) and Director of the University’s Center of Cyber Security, who was associated with research and development posts in cybersecurity and cryptology. Her research interests include unmanned aerial vehicle (UAV) security, cryptology, cryptanalysis, and building security hardware and software components.

Dr Bushra Alblooshi, Head of Research and Innovation at Dubai Electronic Security Center (DESC), who is focused on researching cloud computing, cybersecurity, computer forensics and cryptography.

Prof. Inseok Hwang, Professor at the School of Aeronautics and Astronautics at Purdue University, who specialises in research on intelligent and high assurance autonomy for cyber-physical systems with applications to complex networked systems, such as multi-vehicle systems.

Prof. Dongyan Xu, Samuel D. Conte Professor of Computer Science at Purdue University, specialises in research focused on cyber and cyber-physical security.

Prof. Taesoo Kim is Associate Professor at the School of Computer Science at the Georgia Institute of Technology, and his research interests span systems security architecture and design, threat intelligence, internet infrastructure and operating systems, machine learning, and programming languages.

Prof. Wenke Lee is Professor of Computer Science and John P. Imlay Jr. Chair, College of Computing at the Georgia Institute of Technology, and is one of the most prolific and influential cybersecurity researchers in the world. His research specialty is systems and network security, applied cryptography and machine learning.

Dr Harry Edelman is CEO of architectural consultancy Edelman Group and co-founder of AIDOMUS, a machine learning and IoT-based startup initiative for smart urban services. His work has focused on various aspects of integrated urban developments, including smart urban energy design and mobility.

Dr Shreekant (Ticky) Thakkar, Chief Researcher at Secure Systems Research Centre, said: “The Centre combines fundamental and applied research to set new standards and act as a catalyst to transform problems into solutions. The goal of the research team is to create new technologies for the development of end-to-end security and resilience in cyber-physical and autonomous systems.”

Research in security and resilience in cyber-physical and autonomous systems will ultimately lead to groundbreaking efforts in ensuring the safety and economic prosperity of our communities. The Board of Advisors will guide the expert SSRC researchers in carrying out such cutting-edge research while also creating new opportunities to train aspiring young UAE nationals in these significant fields.

For more information about Secure Systems Research Centre (SSRC), visit tii.ae/securesystems

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye